Ophthalmology

Diabetic eye disease
#Breye Therapeutics #Diabetes #Diabetic macular oedema #Ophthalmology #Phase I trial

Phase Ib trial complete in patients with diabetic retinopathy

Breye Therapeutics is a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases. The company has now completed its Phase Ib clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated oedema. Read More

#News

Test for AMD
#Cell therapy #Clinical trial #Lineage Cell Therapeutics #Ophthalmology

Cell therapy improves visual function in geographic atrophy patients

Lineage Cell Therapeutics revealed new 36-month results from a Phase I/IIa clinical study of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at Clinical Trials at the Summit (CTS) 2025.   OpRegen is a suspension of human allogeneic retinal pigment epithelial (RPE)… Read More

#News

Human eye
#AMD #Monoclonal antibodies #Ophthalmology #Outlook Therapeutics #Scottish Medicines Consortium (SMC)

Bevacizumab gamma gets Scottish OK for wet AMD

The Scottish Medicines Consortium (SMC) has approved Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).   It is the first licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and the UK and has an initial 10 years of… Read More

#News #Regulatory

Cell and gene therapy
#AAV #Financing #Gene therapy #Genetic diseases #Ophthalmology #SpliceBio

SpliceBio secures $135m to advance gene therapy candidates

SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.  There was also participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.  The funding… Read More

#Business & Investment #News

#Gene therapy #Genetic diseases #Ophthalmology #Retinitis pigmentosa

Gene therapies for inherited retinal disorders

Christopher Doyle, PhD, Senior Director of IBC Services at WCG provides an overview of common approaches, emerging trends, and future prospects of gene therapies for inherited retinal disorders. Inherited retinal disorders (IRDs) are a group of genetically diverse conditions that lead to significant vision impairment and often culminate in complete… Read More

#Exclusive Content

Structure of the eye
#Cell therapy #FDA #Neurodegenerative disorders #Neurotech Pharmaceuticals #Ophthalmology

FDA approves first treatment for Macular Telangiectasia Type 2

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel).  MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients' quality of life.   Encelto utilises an encapsulated cell therapy… Read More

#News #Regulatory

Child having an eye test
#Gene therapy #Genetic diseases #MeiraGTx #Ophthalmology #UCL

Gene therapy treats rare genetic sight impairment in the UK

Four young children have gained improvements in their vision following treatment with a new genetic medicine through Moorfields Eye Hospital and UCL Institute of Ophthalmology, with the support of MeiraGTx.  The children were born with a severe impairment to their sight due to a rare genetic deficiency… Read More

#News #Trending News

Optic nerve
#Icahn School of Medicine #Oculis Holding #Ophthalmology #Phase II trial

“Groundbreaking” results in acute optic neuritis trial

A novel peptidomimetic small molecule candidate has met the primary endpoint in a Phase II trial in patients with acute optic neuritis.  Oculis Holding’s neuroprotective candidate OCS-05 also achieved statistical significance on several key efficacy-based secondary endpoints.  The Phase II Acute OptiC NeUrITis of DemYelinating… Read More

#Editor's Choice #News

#Immunocore Holdings #National Institute for Health and Care Excellence (NICE) #Oncology #Ophthalmology

UK’s NICE reverses decision on uveal melanoma therapy

Immunocore Holdings’ Kimmtrak (tebentafusp) has been recommended for funding through the National Health Service (NHS) in England by the National Institute for Health and Care Excellence (NICE).  NICE has recommended KIMMTRAK within its marketing authorisation for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.   The recommendation overturns… Read More

#News #Regulatory

Test for AMD
#Dry AMD #Geographic atrophy #Ophthalmology #PulseSight Therapeutics

Data support transferrin vectorised therapy for geographic atrophy

New data have revealed the potential of a DNA plasmid expressing human transferrin for the treatment of dry age-related macular degeneration (AMD) and geographic atrophy (GA). PulseSight Therapeutics shared the data on its lead programme PST-611 at the European Association for Vision and Eye Research (EVER)… Read More

#News

Human eye
#Gene therapy #Genetics / genomics #Ophthalmology #Rare disease #University of Florida

Gene therapy restores vision in first-of-its-kind trial

A gene therapy developed by University of Florida scientists restored useful vision to most patients with rare condition Leber congenital amaurosis type I (LCA1) in a small trial. Patients who received the highest dose of the gene therapy saw up to a 10,000-fold improvement in their… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Clinical trial design #Collaboration #Exonate #Exploristics #Ophthalmology

Partners enhance trial design using cloud-based simulation

Exploristics and Exonate have announced the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease. The collaboration has supported ongoing development of Exonate’s lead candidate, EXN407, following a recent successful Phase Ib/IIa study in November. Read More

#News

Monoclonal antibodies
#Anti-inflammatory #Financing #Lassen Therapeutics #Monoclonal antibodies #Ophthalmology

$85m fund supports monoclonal antibody for fibro-inflammatory disorders

Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme for LASN01 is focused primarily in… Read More

#Business & Investment #News

Eye health ophthalmology
#Clinical trials #Diabetes #Exonate #Eye health #mRNA #Ophthalmology #Small molecules

Trial in diabetic macular oedema successfully completed  

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study.   During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity. Exonate… Read More

#News

Retinitis pigmentosa
#Clinical trial #Kiora Pharmaceuticals #Ophthalmology #Phase I trial #Retinitis pigmentosa

Molecular photoswitch improves visual acuity in retinitis pigmentosa

Topline results from a Phase I/II clinical trial have shown that Kiora’s light-restoring small molecule KIO-301 has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP). The results of the ABACUS study for Kiora’s intravitreal (IVT) molecular photoswitch were presented at the American… Read More

#News